Beyond the method change in clinical practice: evaluation of insulin-like growth factor I assay.

ABSTRACT:

Objectives

Insulin-like growth factor I (IGF-I) is the preferred biomarker for diagnosing and monitoring growth-related disorders but its serum quantification presents several difficulties since different IGF-I assays still leads to different IGF-I concentrations, especially when results are either above or below the normal range.

Methods

We conducted a prospective study between November and December 2020 at a tertiary University Hospital with 212 serum samples to determine the analytical performance of the IGF-I assay on the Cobas e411 (Roche Diagnostics) and compare it with that of the Immulite 2000XPi (Siemens).

Results

In this work, we report for the first time the existence of discrepancies between IGF-I levels measured by Immulite 2000XPi and Cobas e411. Deming

SUBMITTER: Sienes Bailo P 

PROVIDER: S-EPMC10197437 | biostudies-literature | 2022 Dec

REPOSITORIES: biostudies-literature